iShares Biotechnology ETF (NASDAQ:IBB) Reaches New 52-Week High – Time to Buy?

iShares Biotechnology ETF (NASDAQ:IBB) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $217.12 and last traded at $216.42, with a volume of 706057 shares changing hands. The stock had previously closed at $212.53.

iShares Biotechnology ETF Stock Performance

The firm has a 50-day simple moving average of $191.75 and a two-hundred day simple moving average of $177.76.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were issued a dividend of $0.0238 per share. This represents a $0.10 annualized dividend and a yield of 0.0%. The ex-dividend date of this dividend was Monday, June 15th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IBB. Darwin Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF during the 2nd quarter valued at approximately $25,000. Basepoint Wealth LLC acquired a new stake in iShares Biotechnology ETF during the fourth quarter valued at $26,000. Pension & Wealth Management Advisors Inc. purchased a new position in iShares Biotechnology ETF in the second quarter valued at $28,000. Cary Street Partners Financial LLC purchased a new position in iShares Biotechnology ETF in the fourth quarter valued at $29,000. Finally, Copia Wealth Management acquired a new position in shares of iShares Biotechnology ETF in the fourth quarter worth about $34,000. 62.45% of the stock is owned by institutional investors and hedge funds.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.